20 articles
Study identifies senescent EGR1+ B cells that sabotage immunotherapy in esophageal cancer, with fisetin showing promise as a therapeutic enhancer.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-Ξ³/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Novel nanoparticle combines protein degrader with light therapy to reprogram cancer metabolism and eliminate breast tumors.
A mouse study finds that senolytic drugs cannot prevent chemotherapy-driven bone loss, challenging a leading hypothesis about its cause.
Combining two targeted drugs plus dietary changes shows superior cancer-fighting potential in lab studies of breast and endometrial cancers.
Researchers develop targeted drug that degrades FTO protein, disrupting ribosome production and protein synthesis in leukemia cells.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
Novel nanoplatform delivers copper and iron ions to trigger both ferroptosis and cuproptosis in cancer cells.
Scientists uncover how SCRN1 blocks ferroptosis in liver cancer, revealing new targets for treating drug-resistant hepatocellular carcinoma.
Novel treatment triggers ferroptosis in cancer cells while activating immune responses that further enhance cancer cell death.
Mechanical tension in the tumor microenvironment controls iron metabolism and cell death susceptibility via a novel NCOA4-FTH1 autophagy axis.
Scientists develop brain-penetrating drug that makes glioblastoma cells vulnerable to targeted elimination therapy.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
New study reveals how blocking ribosome production makes cancer cells vulnerable to ferroptosis, an iron-dependent cell death pathway.
Bireociclib plus fulvestrant significantly improved outcomes in advanced hormone-positive breast cancer patients.
New review reveals why fecal microbiota transplants sometimes helpβand sometimes hurtβimmune checkpoint inhibitor cancer treatments.
